Aspire Biopharma delays shareholder meeting to June 16

Aspire Biopharma Holdings, Inc. reported that its shareholder meeting held on June 9, 2026 was adjourned because a quorum was not reached.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. reported that its shareholder meeting held on June 9, 2026 was adjourned because a quorum was not reached. The company has rescheduled the meeting to June 16, 2026 at 10:00 a.m. EST. The online access link remains www.colonialstock.com/AspireBiopharma2026.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Original meeting date: June 9, 2026 New meeting date: June 16, 2026 Meeting time: 10:00 a.m. EST

3 metrics

Original meeting date June 9, 2026 Shareholder meeting adjourned for lack of quorum

New meeting date June 16, 2026 Rescheduled shareholder meeting

Meeting time 10:00 a.m. EST Time for rescheduled June 16, 2026 meeting

Key Terms

quorum, Emerging growth company, shareholder meeting

3 terms

quorum financial

"the Company adjourned its shareholder meeting as a result of not reaching the quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

shareholder meeting financial

"the Company adjourned its shareholder meeting as a result of not reaching the quorum"

A shareholder meeting is a formal gathering where a company's owners—individuals and institutions who hold its stock—review performance, ask questions of management, and vote on important items such as leadership, executive pay, dividend policy, and major transactions. Like a town hall and ballot combined, it matters to investors because decisions made and votes cast there can change who runs the company and how profits are used, directly influencing the value and direction of your investment.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aspire Biopharma (ASBP) disclose in this 8-K filing?

Aspire Biopharma disclosed that its June 9, 2026 shareholder meeting was adjourned because a quorum was not reached. The meeting has been rescheduled to June 16, 2026 at 10:00 a.m. EST with the same online access link.

Why was Aspire Biopharma’s June 9, 2026 shareholder meeting adjourned?

The June 9, 2026 shareholder meeting was adjourned because Aspire Biopharma did not reach a quorum. Without enough shares represented, the company could not conduct official business and therefore moved the meeting to a later date.

When is Aspire Biopharma’s rescheduled shareholder meeting in 2026?

Aspire Biopharma rescheduled its shareholder meeting to June 16, 2026 at 10:00 a.m. EST. This new date follows the adjournment of the original June 9, 2026 meeting due to lack of quorum.

How can shareholders access Aspire Biopharma’s adjourned meeting?

Shareholders can access the adjourned Aspire Biopharma meeting through the link www.colonialstock.com/AspireBiopharma2026. The company stated that this online link will remain the same for the rescheduled June 16, 2026 meeting at 10:00 a.m. EST.

Does Aspire Biopharma’s 8-K mention any changes to meeting logistics?

The 8-K notes a new meeting date and time and confirms the same online link. Aspire Biopharma moved the meeting to June 16, 2026 at 10:00 a.m. EST, keeping www.colonialstock.com/AspireBiopharma2026 as the access point.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/12/2026 - 05:15 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2026

Aspire Biopharma Holdings, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-41293

33-3467744

(State or other jurisdiction

of incorporation)

(Commission

File No.)

(I.R.S. Employer

Identification No.)

23150 Fashion Drive, Suite 232

Estero, Florida 33928

(Address of Principal Executive Offices)

(908) 987-3002

(Registrant’s Telephone Number)

194 Candelaro Drive, # 233

Humacao, PR 00791

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	ASBP	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of common stock	ASBPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On June 9, 2026, the Company adjourned its shareholder meeting as a result of not reaching the quorum. The Company adjourned the meeting and rescheduled it to June 16 at 10:00 a.m. (EST). The link for the adjourned meeting will still be www.colonialstock.com/AspireBiopharma2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 12, 2026

Aspire Biopharma Holdings, Inc.

By:	/s/ Kraig T. Higginson
Name:	Kraig T. Higginson
Title:	Chief Executive Officer and Chairman

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents